Central Retinal-Artery Occlusion: An Ocular Emergency

Central retinal-artery occlusion (CRAO) is a serious condition that requires immediate attention from an ophthalmologist. It is diagnosed through a dilated eye examination that reveals a cherry-red spot in the center of the macula, surrounded by pale retina due to lack of blood flow. Other signs include segmentation of the blood column in the arteries and cattle-trucking.

CRAO is an ocular emergency because the retinal damage becomes irreversible with time, and urgent management is necessary to protect the other eye and the cardiovascular and cerebrovascular systems. The primary goal of management is to re-perfuse ischaemic tissue as quickly as possible and to institute secondary prevention early.

If giant-cell arteritis is suspected, immediate treatment is necessary, including intravenous steroids followed by oral steroids.

Referral under the 2-week-wait rule is necessary when there is a suspicion of cancer, but no signs of a tumor from history or fundoscopy findings.

It is crucial to refer the patient for urgent brain imaging and immediate review by an eye specialist. Starting the patient on topical antibiotics and anti-inflammatories would be inappropriate since there are no signs of an infection process.

Management of Conduct Disorder: Interventions and Referrals

Conduct disorder is a psychiatric condition characterized by persistent patterns of aggressive and antisocial behavior. The management of conduct disorder involves a combination of pharmacological and psychosocial interventions. Here are some of the key interventions and referrals for managing conduct disorder:

Cognitive Behavioral Therapy (CBT): CBT techniques are used as part of the psychosocial interventions for conduct disorder. These techniques are considered as part of the first-line management of conduct disorder.

Methylphenidate: Methylphenidate is a medication that is used in the treatment of ADHD, which is often a coexisting condition with conduct disorder. This medication should only be initiated and coordinated by a specialist in secondary care (such as CAMHS).

Antidepressant Medications: Antidepressant medications should not be the first line in the management of conduct disorder, particularly with no coexisting health conditions. If there were depressive symptoms, these medications could be considered but are generally avoided in this age group.

Psychosocial Interventions: Psychosocial interventions are important in the management of conduct disorder. These include child-focussed programmes, multimodal interventions and parent training programmes. These interventions would be considered first-line management for conduct disorder if there was not the co-existing complicating factor of ADHD.

Referral to Child and Adolescent Mental Health Services (CAMHS): Patients presenting with symptoms of conduct disorder with a significant complicating factor should be referred to CAMHS for specialist assessment. These factors include mental health problems, neurodevelopmental disorder, learning disability or difficulty, and substance misuse. However, if the patient has already been referred to CAMHS, re-referral would not be necessary.

Managing Conduct Disorder: Interventions and Referrals

Children with cows milk protein allergy can use the milk ladder to reintroduce milk protein after they turn 6 months old.

To gradually introduce milk, the milk ladder starts with cooked or baked milk. The process begins with malted milk biscuits and then progresses in a step-by-step manner towards pasteurised milk.

Understanding Cow’s Milk Protein Intolerance/Allergy

Cow’s milk protein intolerance/allergy (CMPI/CMPA) is a condition that affects around 3-6% of children, typically presenting in the first 3 months of life in formula-fed infants. Both immediate and delayed reactions can occur, with CMPA used for immediate reactions and CMPI for mild-moderate delayed reactions. Symptoms include regurgitation, vomiting, diarrhea, urticaria, atopic eczema, colic symptoms, wheeze, chronic cough, and rarely, angioedema and anaphylaxis. Diagnosis is often clinical, with investigations including skin prick/patch testing and total IgE and specific IgE (RAST) for cow’s milk protein.

Management for formula-fed infants includes using extensive hydrolyzed formula (eHF) milk as the first-line replacement formula for mild-moderate symptoms and amino acid-based formula (AAF) for severe CMPA or if no response to eHF. Around 10% of infants are also intolerant to soya milk. For breastfed infants, mothers should eliminate cow’s milk protein from their diet and consider prescribing calcium supplements to prevent deficiency. eHF milk can be used when breastfeeding stops until at least 6 months and up to 12 months of age.

The prognosis for CMPI is usually good, with most children becoming milk tolerant by the age of 3-5 years. However, a challenge is often performed in a hospital setting as anaphylaxis can occur. It is important to refer infants with severe symptoms to a pediatrician for management. Understanding CMPI/CMPA and its management can help parents and healthcare providers provide appropriate care for affected children.

A central scotoma is a common feature of optic neuritis, along with visual loss, periocular pain, and dyschromatopsia (change in colour perception). Other classic signs on examination include a relative afferent pupillary defect. Unlike open-angle glaucoma, which typically causes painless, gradual loss of peripheral vision, optic neuritis often affects the central vision. Anterior ischaemic optic neuropathy, on the other hand, causes sudden, painless loss of vision and is more common in people over 50. Optic nerve glioma, which is rare after age 20 and may be associated with neurofibromatosis, can cause visual defects and headaches but is not typically associated with eye movement pain or colour desaturation.

Optic neuritis is a condition that can be caused by multiple sclerosis, diabetes, or syphilis. It is characterized by a decrease in visual acuity in one eye over a period of hours or days, as well as poor color discrimination and pain that worsens with eye movement. Other symptoms include a relative afferent pupillary defect and a central scotoma. The condition can be diagnosed through an MRI of the brain and orbits with gadolinium contrast. Treatment typically involves high-dose steroids, and recovery usually takes 4-6 weeks. If an MRI shows more than three white-matter lesions, the risk of developing multiple sclerosis within five years is approximately 50%.

For patients with active hormone-responsive breast cancer, hormonal methods like HRT and tibolone are not recommended. Instead, non-hormonal methods like selective serotonin reuptake inhibitors and venlafaxine may be used to alleviate vasomotor symptoms of menopause. Topical estrogen can also be used to alleviate symptoms of vaginal atrophy, but it does not help with vasomotor symptoms. COCP is not a suitable treatment for menopausal symptoms.

Managing Menopause: Lifestyle Modifications, Hormone Replacement Therapy, and Non-Hormone Replacement Therapy

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is diagnosed when a woman has not had a period for 12 consecutive months. Menopausal symptoms are common and can last for up to 7 years, with varying degrees of severity and duration. The management of menopause can be divided into three categories: lifestyle modifications, hormone replacement therapy (HRT), and non-hormone replacement therapy.

Lifestyle modifications can help manage menopausal symptoms such as hot flushes, sleep disturbance, mood changes, and cognitive symptoms. Regular exercise, weight loss, stress reduction, and good sleep hygiene are recommended. For women who cannot or do not want to take HRT, non-hormonal treatments such as fluoxetine, citalopram, or venlafaxine for vasomotor symptoms, vaginal lubricants or moisturizers for vaginal dryness, and cognitive behavior therapy or antidepressants for psychological symptoms can be prescribed.

HRT is a treatment option for women with moderate to severe menopausal symptoms. However, it is contraindicated in women with current or past breast cancer, any estrogen-sensitive cancer, undiagnosed vaginal bleeding, or untreated endometrial hyperplasia. HRT brings certain risks, including venous thromboembolism, stroke, coronary heart disease, breast cancer, and ovarian cancer. Women should be advised of these risks and the fact that symptoms typically last for 2-5 years.

When stopping HRT, it is important to gradually reduce the dosage to limit recurrence of symptoms in the short term. However, in the long term, there is no difference in symptom control. Women who experience ineffective treatment, ongoing side effects, or unexplained bleeding should be referred to secondary care. Overall, managing menopause requires a personalized approach that takes into account a woman’s medical history, preferences, and individual symptoms.

Medical Conditions and Their Association with Nasal Polyps

Nasal polyps are abnormal growths that develop in the lining of the nasal passages or sinuses. While they can occur in anyone, certain medical conditions may increase the likelihood of their development. Here are some medical conditions and their association with nasal polyps:

Kartagener Syndrome: This rare autosomal recessive condition is characterized by primary ciliary dyskinesia and situs inversus. Patients with this condition tend to develop chronic sinusitis, bronchiectasis, recurrent chest and ENT infections, and nasal polyps.

Autoimmune Haemolytic Anaemia: This condition is characterized by fatigue, shortness of breath, palpitations, and jaundice as a consequence of haemolysis driving high levels of bilirubin. However, it does not affect the nose and is not linked to nasal polyps.

Crohn’s Disease: This inflammatory bowel disease can affect any part of the gastrointestinal (GI) tract and can also cause extraintestinal manifestations such as arthritis, iritis, and rashes. However, nasal polyps are not associated with this condition.

Diabetes Mellitus: While nasal polyps are not associated with diabetes mellitus, other conditions including coeliac disease, polycystic ovarian syndrome, and thyroid dysfunction can all develop in affected individuals.

Hereditary Spherocytosis: This condition is characterized by abnormally shaped erythrocytes and symptoms such as fatigue and shortness of breath. Clinical signs include pallor, jaundice, and splenomegaly. However, nasal polyps are not associated with this condition.

The diagnosis that needs to be ruled out first is obstetric cholestasis, as it can heighten the chances of premature birth and fetal death. The condition is identified by abnormal liver function tests and itching without any skin rash. Unlike uric acid, it is the bile acids that are elevated in obstetric cholestasis.

Liver Complications During Pregnancy

During pregnancy, there are several liver complications that may arise. One of the most common is intrahepatic cholestasis of pregnancy, which occurs in about 1% of pregnancies and is typically seen in the third trimester. Symptoms include intense itching, especially in the palms and soles, as well as elevated bilirubin levels. Treatment involves the use of ursodeoxycholic acid for relief and weekly liver function tests. Women with this condition are usually induced at 37 weeks to prevent stillbirth, although maternal morbidity is not typically increased.

Another rare complication is acute fatty liver of pregnancy, which may occur in the third trimester or immediately after delivery. Symptoms include abdominal pain, nausea and vomiting, headache, jaundice, and hypoglycemia. Severe cases may result in pre-eclampsia. ALT levels are typically elevated, and support care is the primary management until delivery can be performed once the patient is stabilized.

Finally, conditions such as Gilbert’s and Dubin-Johnson syndrome may be exacerbated during pregnancy. Additionally, HELLP syndrome, which stands for haemolysis, elevated liver enzymes, and low platelets, is a serious complication that can occur in the third trimester and requires immediate medical attention. Overall, it is important for pregnant women to be aware of these potential liver complications and to seek medical attention if any symptoms arise.

Understanding Personality Disorders: Emotionally Unstable Personality Disorder

Personality disorders are complex and severe disturbances in an individual’s character and behavior, often leading to personal and social disruption. These disorders are challenging to treat, but psychological and pharmacological interventions can help manage symptoms. One of the most common types of personality disorder is borderline personality disorder, characterized by intense emotions, unstable relationships, impulsive behavior, and anxieties about abandonment. Schizoid personality disorder, avoidant personality disorder, dependent personality disorder, and narcissistic personality disorder are other types of personality disorders, each with their own unique symptoms. However, the patient in this scenario is most consistent with borderline personality disorder. Understanding personality disorders is crucial in providing appropriate treatment and support for individuals struggling with these conditions.

Contraception is still necessary after menopause. Women who are over 50 years old should use contraception for at least 12 months after their last period, while those under 50 years old should use it for at least 24 months after their last period.

Understanding Menopause and Contraception

Menopause is a natural biological process that marks the end of a woman’s reproductive years. On average, women in the UK experience menopause at the age of 51. However, prior to menopause, women may experience a period known as the climacteric. During this time, ovarian function starts to decline, and women may experience symptoms such as hot flashes, mood swings, and vaginal dryness.

It is important for women to understand that they can still become pregnant during the climacteric period. Therefore, it is recommended to use effective contraception until a certain period of time has passed. Women over the age of 50 should use contraception for 12 months after their last period, while women under the age of 50 should use contraception for 24 months after their last period. By understanding menopause and the importance of contraception during the climacteric period, women can make informed decisions about their reproductive health.

Premature Ovarian Insufficiency: Causes and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flushes, night sweats, infertility, secondary amenorrhoea, raised FSH and LH levels, and low oestradiol.

Management of premature ovarian insufficiency involves hormone replacement therapy (HRT) or a combined oral contraceptive pill until the age of the average menopause, which is 51 years. It is important to note that HRT does not provide contraception in case spontaneous ovarian activity resumes. Early diagnosis and management of premature ovarian insufficiency can help alleviate symptoms and improve quality of life for affected women.

Hypersensitivity Reactions: Types and Examples

Hypersensitivity reactions are immune responses that can cause tissue damage and inflammation. There are four types of hypersensitivity reactions, each with different mechanisms and clinical presentations.

Type I hypersensitivity reaction is an immediate hypersensitivity reaction mediated by IgE in response to an innocuous environmental antigen. Examples of such reactions are allergic rhinitis and systemic urticaria.

Type II hypersensitivity reaction is an antibody-mediated reaction. Cellular injury may result from complement activation, antibody-dependent cell-mediated cytotoxicity or phagocytosis. Examples include incompatible blood transfusions, haemolytic disease of the newborn and autoimmune haemolytic anaemias.

Type III hypersensitivity reaction is an immune complex-mediated reaction. Immune complexes are lattices of antibody and antigen. When these are not cleared from the circulation, they may trigger an inflammatory response. An example of this type of reaction is extrinsic allergic alveolitis, otherwise known as ‘bird fancier’s lung’, a hypersensitivity pneumonitis caused by exposure to bird droppings.

Type IV hypersensitivity reaction is a delayed hypersensitivity reaction involving T helper cells that become activated upon contact with an antigen, which results in a clonal expansion over 1–2 weeks. Repeated exposure to the antigen results in cytokine release from sensitised T-cells, leading to macrophage-induced phagocytosis.

Anaphylaxis is a type I-mediated hypersensitivity reaction, involving the release of inflammatory mediators (such as histamine), which precipitate vasodilatation and oedema. Anaphylaxis is characterised by the rapid onset of respiratory and circulatory compromise.

Understanding the different types of hypersensitivity reactions is important for diagnosis and treatment. Treatment may involve removal of the source of hypersensitivity, immunosuppressive therapy, or administration of epinephrine in the case of anaphylaxis.

Managing Hypothyroidism in an Elderly Patient: Recommended Treatment and Monitoring

For an elderly patient with overt hypothyroidism, immediate treatment is recommended by the National Institute for Health and Care Excellence (NICE). The recommended starting dose of levothyroxine is 25 µg once daily, with regular monitoring of response every 3-4 weeks until a stable TSH has been achieved. After that, a blood test should be performed at 4-6 months and annually thereafter. The goal of treatment is to resolve symptoms and signs of hypothyroidism, normalize TSH and T3/T4 levels, and avoid overtreatment, especially in elderly patients who are at risk of developing cardiac disease. Inappropriate treatments, such as carbimazole or radio-iodine therapy, should be avoided. It is crucial to avoid overtreatment, as it can worsen the patient’s condition and put them at risk of developing myxoedema coma, which can be life-threatening.

The most prevalent cause of meningococcal disease in children in the UK is currently Meningitis B. In 2015, the Meningitis B vaccination was added to the NHS routine childhood immunisation schedule. It is administered at 2, 4, and 12 months of age, in conjunction with other immunisations in the schedule. If given at a different time, doses must be spaced at least 2 months apart. For children over one year old, only two doses are necessary.

Meningitis B Vaccine Now Part of Routine NHS Immunisation

Children in the UK have been vaccinated against meningococcus serotypes A and C for many years, leaving meningococcal B as the most common cause of bacterial meningitis in the country. However, a new vaccine called Bexsero has been developed to combat this strain. Initially, the Joint Committee on Vaccination and Immunisation (JCVI) rejected the use of Bexsero due to a cost-benefit analysis. However, the decision was eventually reversed, and the vaccine has been added to the routine NHS immunisation schedule.

The vaccine is administered in three doses at 2 months, 4 months, and 12-13 months. Additionally, Bexsero will be available on the NHS for individuals at high risk of meningococcal disease, such as those with asplenia, splenic dysfunction, or complement disorder. This new vaccine is a significant step in protecting children and vulnerable individuals from meningitis B.

Cholestyramine is an effective treatment for bile-acid malabsorption. It functions by binding to bile acids in the small intestine and facilitating their reabsorption into the bile acid production cycle. This approach addresses the root cause of diarrhea in patients with this condition. In the case of the patient described, the removal of her gallbladder likely disrupted the normal cycle of bile release and reabsorption, leading to excessive bile in the large intestine and resulting in increased water and salt loss in the stool and faster transit time of stool through the intestines. While bismuth may be useful in preventing symptoms during infectious diarrhea, it is not a long-term solution. Creon is typically used to replace pancreatic enzymes in conditions such as cystic fibrosis, where there is a reduction in pancreatic enzymes reaching the intestine. Loperamide may be effective in preventing diarrhea in the short term, but it does not address the underlying cause of the patient’s condition.

Understanding Bile-Acid Malabsorption

Bile-acid malabsorption is a condition that can cause chronic diarrhea. It can be primary, which means that it is caused by excessive production of bile acid, or secondary, which is due to an underlying gastrointestinal disorder that reduces bile acid absorption. This condition can lead to steatorrhea and malabsorption of vitamins A, D, E, and K. Secondary causes are often seen in patients with ileal disease, such as Crohn’s disease, as well as those who have undergone cholecystectomy, have coeliac disease, or have small intestinal bacterial overgrowth.

To diagnose bile-acid malabsorption, the test of choice is SeHCAT, a nuclear medicine test that uses a gamma-emitting selenium molecule in selenium homocholic acid taurine or tauroselcholic acid. Scans are done 7 days apart to assess the retention or loss of radiolabeled 75SeHCAT.

The management of bile-acid malabsorption involves the use of bile acid sequestrants, such as cholestyramine. These medications work by binding to bile acids in the intestine, preventing their reabsorption and promoting their excretion. With proper management, the symptoms of bile-acid malabsorption can be controlled, and patients can lead a normal life.

Amiodarone is known to cause pulmonary fibrosis, which is evident in the patient’s symptoms of dyspnea and restrictive lung disease on spirometry. However, other potential causes of restrictive lung disease should be investigated before attributing it solely to amiodarone use. Amiodarone can also lead to liver injury and thyroid dysfunction, so monitoring liver and thyroid function is important during treatment.

Ramipril, an ACE inhibitor, commonly causes a persistent dry cough, which is the most frequently reported side effect and often leads to discontinuation of treatment. The exact mechanism of cough production is unclear, but it may involve increased levels of kinins and substance P due to ACE inhibition. Substituting with another antihypertensive drug, such as an angiotensin II receptor blocker, is typically necessary to alleviate the cough.

Aspirin can exacerbate asthma in susceptible individuals, particularly those with Samter’s triad (nasal polyps, asthma, and aspirin sensitivity). However, the patient’s restrictive lung disease is not associated with aspirin use.

Beta blockers like bisoprolol can cause bronchoconstriction in patients with asthma and COPD, making them contraindicated in asthma and requiring caution in COPD. However, the patient’s spirometry results suggest pulmonary fibrosis rather than bronchospasm.

Furosemide can rarely cause bronchoconstriction, but it is not associated with the restrictive lung disease seen in this patient.

Statin therapy is not recommended during pregnancy

The correct statement is that all statins, including atorvastatin, are not recommended during pregnancy due to potential risks to the developing fetus. While there is no conclusive evidence of teratogenicity, there have been reports of adverse outcomes such as intrauterine growth restriction and fetal demise in women taking statins during the first trimester. Lipophilic statins like atorvastatin can cross the placenta and reach similar concentrations in both the mother and fetus.

Clozapine is not a contraindication during pregnancy, as it is an atypical antipsychotic used to treat schizophrenia that is unresponsive to other medications. While caution is advised when using clozapine during pregnancy, it is not considered a contraindication.

Lamotrigine is also not contraindicated during pregnancy, as it is generally considered safe for use in pregnant women. Unlike many other antiepileptic drugs, lamotrigine has not been associated with an increased risk of congenital malformations.

Low-molecular-weight-heparin is also not contraindicated during pregnancy, and is often prescribed for women with antiphospholipid syndrome to prevent blood clots. This medication does not cross the placenta and is considered safe for use during pregnancy.

Statins are drugs that inhibit the action of an enzyme called HMG-CoA reductase, which is responsible for producing cholesterol in the liver. However, they can cause some adverse effects such as myopathy, which includes muscle pain, weakness, and damage, and liver impairment. Myopathy is more common in lipophilic statins than in hydrophilic ones. Statins may also increase the risk of intracerebral hemorrhage in patients who have had a stroke before. Therefore, they should be avoided in these patients. Statins should not be taken during pregnancy and should be stopped if the patient is taking macrolides.

Statins are recommended for people with established cardiovascular disease, those with a 10-year cardiovascular risk of 10% or more, and patients with type 2 diabetes mellitus. Patients with type 1 diabetes mellitus who were diagnosed more than 10 years ago, are over 40 years old, or have established nephropathy should also take statins. It is recommended to take statins at night as this is when cholesterol synthesis takes place. Atorvastatin 20mg is recommended for primary prevention, and the dose should be increased if non-HDL has not reduced for 40% or more. Atorvastatin 80 mg is recommended for secondary prevention. The graphic shows the different types of statins available.

When a seizure is suspected to be caused by eclampsia, the recommended first-line treatment is intravenous magnesium sulfate, given as a loading dose followed by an infusion. In the case of convulsive status epilepticus, intravenous lorazepam is the preferred in-hospital treatment, with phenytoin as an alternative if lorazepam is ineffective. Glucose may be administered if hypoglycemia is a contributing factor. It is not appropriate to administer oral medications to a patient with a decreased level of consciousness. (Adapted from BMJ Best Practice – Pre-eclampsia)

Understanding Eclampsia and its Treatment

Eclampsia is a condition that occurs when seizures develop in association with pre-eclampsia, a pregnancy-induced hypertension that is characterized by proteinuria and occurs after 20 weeks of gestation. To prevent seizures in patients with severe pre-eclampsia and treat seizures once they develop, magnesium sulphate is commonly used. However, it is important to note that this medication should only be given once a decision to deliver has been made. In cases of eclampsia, an IV bolus of 4g over 5-10 minutes should be given, followed by an infusion of 1g/hour. During treatment, it is crucial to monitor urine output, reflexes, respiratory rate, and oxygen saturations. Respiratory depression can occur, and calcium gluconate is the first-line treatment for magnesium sulphate-induced respiratory depression. Treatment should continue for 24 hours after the last seizure or delivery, as around 40% of seizures occur post-partum. Additionally, fluid restriction is necessary to avoid the potentially serious consequences of fluid overload.

In summary, understanding the development of eclampsia and its treatment is crucial in managing this potentially life-threatening condition. Magnesium sulphate is the primary medication used to prevent and treat seizures, but it should only be given once a decision to deliver has been made. Monitoring vital signs and urine output is essential during treatment, and calcium gluconate should be readily available in case of respiratory depression. Finally, fluid restriction is necessary to avoid complications associated with fluid overload.

Understanding Molluscum Contagiosum

Molluscum contagiosum is a viral skin infection that is commonly seen in children, particularly those with atopic eczema. It is caused by the molluscum contagiosum virus and can be transmitted through direct contact or contaminated surfaces. The infection presents as pinkish or pearly white papules with a central umbilication, which can appear anywhere on the body except for the palms of the hands and soles of the feet. In children, lesions are commonly seen on the trunk and in flexures, while in adults, sexual contact may lead to lesions developing on the genitalia, pubis, thighs, and lower abdomen.

While molluscum contagiosum is a self-limiting condition that usually resolves within 18 months, it is important to avoid sharing towels, clothing, and baths with uninfected individuals to prevent transmission. Scratching the lesions should also be avoided, and treatment may be considered if the itch is problematic. However, treatment is not usually recommended, and if necessary, simple trauma or cryotherapy may be used. In some cases, referral may be necessary, such as for individuals who are HIV-positive with extensive lesions or those with eyelid-margin or ocular lesions and associated red eye.

Overall, understanding molluscum contagiosum and taking appropriate precautions can help prevent transmission and alleviate symptoms.

Hypocalcaemia is a sign that the patient’s kidney disease is chronic rather than acute. This is because chronic renal failure can result in a lack of conversion of 25-hydroxyvitamin D to its active form, which is necessary for intestinal calcium absorption. As a result, hypocalcaemia is a marker that suggests the kidney disease is chronic and not acute. Anuria, haematuria, and normal parathyroid hormone levels are not indicative of chronic kidney disease. Most patients with chronic kidney disease are asymptomatic until very late-stage renal disease occurs, at which point they may experience other symptoms such as oedema, anaemia, and pruritus. Oliguria is more suggestive of an acute kidney injury in this scenario.

Distinguishing between Acute Kidney Injury and Chronic Kidney Disease

One of the most effective ways to differentiate between acute kidney injury (AKI) and chronic kidney disease (CKD) is through the use of renal ultrasound. In most cases, patients with CKD will have small kidneys that are bilateral. However, there are some exceptions to this rule, including individuals with autosomal dominant polycystic kidney disease, diabetic nephropathy in its early stages, amyloidosis, and HIV-associated nephropathy.

In addition to renal ultrasound, there are other features that can suggest CKD rather than AKI. For example, individuals with CKD may experience hypocalcaemia due to a lack of vitamin D. By identifying these distinguishing factors, healthcare professionals can more accurately diagnose and treat patients with kidney disease. Proper diagnosis is crucial, as the treatment and management of AKI and CKD differ significantly.

Primary amenorrhoea is caused by Turner’s syndrome instead of secondary amenorrhoea.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods in women. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

There are various causes of amenorrhoea, including gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, Sheehan’s syndrome, Asherman’s syndrome, and thyrotoxicosis. To determine the underlying cause of amenorrhoea, initial investigations such as full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels are necessary.

The management of amenorrhoea depends on the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause in women 40 years of age or older and treat the underlying cause accordingly. It is important to note that hypothyroidism may also cause amenorrhoea.